Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines
Gut
; 70(Suppl 4):A3-A4, 2021.
Article
in English
| ProQuest Central | ID: covidwho-1506204
ABSTRACT
OFR-8 Figure 1ConclusionsInfliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab.
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Topics:
Vaccines
Language:
English
Journal:
Gut
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS